Raymond James Financial
KRYS icon

Raymond James Financial’s Krystal Biotech KRYS Stock Holding History

Raymond James Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.5M Buy
156,064
+79,526
+104% +$21.2M 0.01% 1004
2025
Q4 		$19M Buy
76,538
+12,175
+19% +$2.56M 0.01% 1485
2025
Q3 		$11.4M Sell
64,363
-4,372
-6% -$654K ﹤0.01% 1815
2025
Q2 		$9.45M Buy
68,735
+2,774
+4% +$407K ﹤0.01% 1918
2025
Q1 		$11.9M Sell
65,961
-36,100
-35% -$6.07M ﹤0.01% 1679
2024
Q4 		$16M Buy
+102,061
New +$18.1M 0.01% 1485

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's KRYS Position: Q1 2026 in Review

Raymond James Financial increased its Krystal Biotech (KRYS) stake by 104% in Q1 2026, buying an estimated $21.2M and bringing the position to 156,064 shares worth $39.5M. The position accounts for 0.01% of the portfolio, ranked #1004.

Raymond James Financial first reported a position in KRYS in Q4 2024 and has held it in 6 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Raymond James Financial held 156,064 shares of Krystal Biotech worth $39.5M as of Q1 2026.
  • Raymond James Financial bought 79,526 Krystal Biotech shares in Q1 2026, an estimated $21.2M.
  • Krystal Biotech made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1004 holding.
  • Raymond James Financial first reported a position in Krystal Biotech in Q4 2024 and has held it in 6 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.